M. Lassus

2.7k total citations · 1 hit paper
20 papers, 1.3k citations indexed

About

M. Lassus is a scholar working on Cardiology and Cardiovascular Medicine, Oncology and Genetics. According to data from OpenAlex, M. Lassus has authored 20 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Cardiology and Cardiovascular Medicine, 7 papers in Oncology and 7 papers in Genetics. Recurrent topics in M. Lassus's work include Estrogen and related hormone effects (6 papers), Pregnancy and preeclampsia studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). M. Lassus is often cited by papers focused on Estrogen and related hormone effects (6 papers), Pregnancy and preeclampsia studies (4 papers) and Cancer Treatment and Pharmacology (3 papers). M. Lassus collaborates with scholars based in Switzerland, United Kingdom and Russia. M. Lassus's co-authors include Hilary A. Chaudri‐Ross, L. Mauriac, J. Eremin, Margaret Dugan, Stefan Paepke, J. Vinholes, Semiglazov Vf, Matthew J. Ellis, W. Eiermann and Antonio Llombart‐Cussac and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Lassus

18 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

2001 530 citations W. Eiermann, Stefan Paepke et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Lassus Switzerland	12	720	671	659	277	197	20	1.3k
A. Buzdar United States	7	1.2k 1.6×	1.2k 1.8×	846 1.3×	356 1.3×	253 1.3×	16	2.0k
Aman U. Budzar United Kingdom	4	897 1.2×	1.1k 1.6×	801 1.2×	319 1.2×	227 1.2×	4	1.6k
Pamela Guglielmini Italy	13	577 0.8×	595 0.9×	468 0.7×	166 0.6×	148 0.8×	24	1.0k
N.J. Bundred United Kingdom	17	744 1.0×	760 1.1×	437 0.7×	246 0.9×	311 1.6×	38	1.5k
Vincent O. Dezentjé Netherlands	18	592 0.8×	420 0.6×	405 0.6×	169 0.6×	195 1.0×	54	1.2k
J Wolter United States	14	665 0.9×	383 0.6×	567 0.9×	205 0.7×	116 0.6×	25	1.0k
Ignasi Tusquets Spain	23	970 1.3×	448 0.7×	627 1.0×	219 0.8×	608 3.1×	73	1.9k
TJ Powles United Kingdom	19	991 1.4×	1.2k 1.8×	472 0.7×	200 0.7×	346 1.8×	39	1.9k
D. G. Kieback Germany	14	530 0.7×	372 0.6×	393 0.6×	248 0.9×	221 1.1×	31	946
Nan Soon Wong Singapore	20	686 1.0×	217 0.3×	321 0.5×	192 0.7×	241 1.2×	39	1.1k

Countries citing papers authored by M. Lassus

Since Specialization

Citations

This map shows the geographic impact of M. Lassus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Lassus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Lassus more than expected).

Fields of papers citing papers by M. Lassus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Lassus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Lassus. The network helps show where M. Lassus may publish in the future.

Co-authorship network of co-authors of M. Lassus

This figure shows the co-authorship network connecting the top 25 collaborators of M. Lassus. A scholar is included among the top collaborators of M. Lassus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Lassus. M. Lassus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lassus, M., et al.. (2024). Detección de rigidez arterial en mujeres con antecedente reciente de preeclampsia. Hipertensión y Riesgo Vascular. 42(1). 3–12.

Lassus, M., et al.. (2022). Síndrome nefrótico secundario a preeclampsia: presentación, manejo y evolución clínica observados en 5 años de experiencia. Hipertensión y Riesgo Vascular. 40(1). 16–24. 2 indexed citations

Lassus, M., et al.. (2020). Síndrome HELLP: características clínicas, analíticas y evolutivas observadas en dos años de experiencia. Hipertensión y Riesgo Vascular. 37(4). 152–161. 7 indexed citations

Lassus, M., et al.. (2018). Utilidad del índice neutrófilo/linfocito y del índice polimorfonuclear/monomorfonuclear, en la predicción de preeclampsia. Hipertensión y Riesgo Vascular. 36(2). 63–69. 4 indexed citations

Keilholz, Ulrich, Alexander Schmittel, Konrad Klinghammer, et al.. (2017). First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. European Journal of Cancer. 80. 14–25. 9 indexed citations

Lassus, M., et al.. (2013). Bruit et induction anesthésique : enquête au sein des équipes d’anesthésie et de bloc opératoire. Annales Françaises d Anesthésie et de Réanimation. 32. A412–A413.

Saccardi, Riccardo, Alan Tyndall, Gerry Coghlan, et al.. (2004). Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplantation. 34(10). 877–881. 48 indexed citations

Eiermann, W., Stefan Paepke, Antonio Llombart‐Cussac, et al.. (2001). Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Annals of Oncology. 12(11). 1527–1532. 530 indexed citations breakdown →

Schr�der, F.H., et al.. (2000). Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?. The Prostate. 42(2). 107–115. 24 indexed citations

10.

Gershanovich, M., Daniel de Castro, H. Lurie, et al.. (1999). [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].. PubMed. 45(4). 361–8. 1 indexed citations

11.

Gershanovich, M., H.A. Chaudri, H. Lurie, et al.. (1998). Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals of Oncology. 9(6). 639–645. 206 indexed citations

12.

Gardin, G., A. Fornasiero, Gilles Romieu, et al.. (1998). Long duration of response with letrozole 2.5 mg (Femara®) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy. European Journal of Cancer. 34. S13–S14. 2 indexed citations

13.

Brufman, G, E Colajori, N. Ghilezan, et al.. (1997). Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. Annals of Oncology. 8(2). 155–162. 64 indexed citations

14.

Sessa, Cristiana, Olivia Pagani, Maria Grazia Zurlo, et al.. (1994). Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Annals of Oncology. 5(10). 901–907. 40 indexed citations

15.

Feld, Ronald, Ryszard Wierzbicki, Frances A. Shepherd, et al.. (1992). Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 10(2). 297–303. 42 indexed citations

16.

Salle, E. Di, G. Ornati, D. Giudici, et al.. (1992). Exemestane (FCE 24304), A new steroidal aromatase inhibitor. The Journal of Steroid Biochemistry and Molecular Biology. 43(1-3). 137–143. 75 indexed citations

17.

Evans, T.R. Jeffry, E. Di Salle, G. Ornati, et al.. (1992). Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.. PubMed. 52(21). 5933–9. 129 indexed citations

18.

Leyvraz, Serge, T Ohnuma, M. Lassus, & J F Holland. (1985). Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.. Journal of Clinical Oncology. 3(10). 1385–1392. 54 indexed citations

19.

Cumberlin, Richard L., et al.. (1985). Isolation perfusion for malignant melanoma of the extremity: a review.. Journal of Clinical Oncology. 3(7). 1022–1031. 40 indexed citations

20.

McGovren, J. Patrick, Kenneth G. Nelson, M. Lassus, et al.. (1984). Menogaril: a new anthracycline agent entering clinical trials. Investigational New Drugs. 2(4). 359–367. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact